Natco Pharma opened at ₹800.55, in line with its previous close of ₹800.55. During today's session, the stock has traded between ₹787.20 and ₹802.65, with an average traded price of ₹792.06. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Natco Pharma is now worth
₹ 8,905.00
resulting in a loss of
₹ 1,095.00 (10.95%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-11.40 (-1.42%)
Day High
₹802.65
Day Low
₹787.20
Day Open
₹800.55
Prev Close
₹800.55
Volume
2,77,749
Value Traded
₹22.00 Cr
1W Return
-3.94%
1M Return
-2.42%
3M Return
-19.15%
6M Return
-27.95%
1Y Return
-5.93%
Market Cap (₹ Cr.)
15,481
PE Ratio
13.70
PB Ratio
1.49
Dividend Yield
0.19%
ROE
14.88%
ROCE
16.26%
Book Value (₹)
535.28
Face Value (₹)
2.00
EPS (TTM)
11.53
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-3.94%
6 Week
-
1 Month
-2.42%
3 Month
-19.15%
9 Month
-7.25%
Natco Pharma promoter pledges 8.5 lakh shares to Bajaj Financial
V.C. Nannapaneni pledged 8,50,000 Natco Pharma shares to Bajaj Financial Securities Limited. The pledged shares represent 0.47% of Natco Pharma's total share capital. Date of pledge creation was October 9, 2026, disclosed on October 12, 2026. Promoter holds 2,80,45,905 shares, constituting 15.66% of total capital.
TodayNatco Pharma shareholders approve ₹2,000 crore fund raise proposal
Natco Pharma shareholders approved a ₹2,000 crore fund raise proposal with 98.94% votes in favour. Three interim dividends aggregating ₹5.00 per share were confirmed for FY26. Institutional investors showed highest dissent (4.21%) against the fund raise resolution. All other resolutions, including director re-appointment and auditor ratification, passed with >99% support.
13 days agoNatco Pharma approves Letter of Offer for ₹1,279 crore rights issue
Natco Pharma approved the Letter of Offer for its ₹1,279.36 crore rights issue on September 28, 2026. Record date for eligibility is set at October 1, 2026, with subscription opening October 12. Issue price is fixed at ₹750 per share, comprising a premium of ₹748 over face value. Rights entitlement ratio is 2 shares for every 21 held, with tradable rights from Oct 12-16.
15 days agoNatco Pharma raises investment in eGenesis to $24.70 million
Natco Pharma increased its investment in eGenesis to $16.70 million, raising total stake to $24.70 million. The investment is made via convertible promissory notes with an 8% annual interest rate. Funds are deployed through two subsidiaries: NATCO Pharma (Canada) Inc. ($13.70 million) and NATCO Pharma USA LLC ($3 million). Completion of the acquisition is targeted for October 31, 2026.
15 days agoNatco Pharma board approves ₹1,300 crore rights issue
Natco Pharma board approved ₹1,300 crore rights issue on September 9, 2026. Draft letter of offer for the rights issue was also approved by the board. Fundraising replaces earlier broader mandate for equity or other securities. Pending demerger scheme for Natco Crop Health Sciences must be revised.
1mo agoNatco Pharma files FY26 annual report, schedules AGM for September 30
Natco Pharma Ltd filed its annual report for FY26 with BSE and NSE. The 43rd AGM is scheduled for September 30, 2026, at 11:00 am. The meeting will be held via video conferencing as per SEBI regulations. The annual report is accessible on the company's investor relations page.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in Natco Pharma is now worth
₹ 8,905.00
resulting in a loss of
₹ 1,095.00 (10.95%)
Note: Past profits do not guarantee future returns.
